Los Angeles, CA & Vancouver, BC, June 09, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig”), which acquired Streamex Exchange Corporation as its wholly owned subsidiary (“Streamex”) in May 2025, is pleased to announce the appointment of Trevor Bacon and Kellan Grenier, co-founders of Parcl, as Strategic Advisors. Together, they bring deep expertise at the intersection of decentralized finance, synthetic asset creation, and real-world asset tokenization. Parcl is a leading blockcha ...

Core Insights - BioSig Technologies, Inc. has appointed Sean Roosen as Strategic Advisor to its wholly owned subsidiary, Streamex Exchange Corporation, following its acquisition in May 2025 [1] - Sean Roosen is a prominent figure in the mining industry with over 30 years of experience, having founded and led multiple successful resource ventures [2][3] - Streamex aims to revolutionize commodity markets through real-world asset tokenization, enhancing liquidity and accessibility in the financial sector [6][8] Company Overview - BioSig Technologies, Inc. is a medical device technology company known for its PURE EP™ Platform, which aids electrophysiologists in treating cardiovascular arrhythmias [9] - Streamex focuses on tokenizing real-world assets in the commodities space, developing infrastructure for primary issuance and exchange [6][8] Leadership and Expertise - Sean Roosen has a notable track record, including founding Osisko Development Corp. and leading Osisko Mining Corporation, which developed the Canadian Malartic mine [2][3] - The advisory board of Streamex includes other industry leaders, such as Frank Giustra, who has founded companies with significant market capitalizations [7] Strategic Vision - The company believes in the future of finance being driven by tokenization and decentralized markets, aiming to bridge traditional finance with the digital economy [8] - Roosen expressed enthusiasm about joining Streamex, highlighting the potential of bringing the resource sector into the digital age through tokenized assets [5]

Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced the appointment of Mitch Williams, CFA, as Chief Investment Officer significantly bolstering the companies’ leadership team and advancing the mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment: Mr. Mitch Williams, form ...

Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the “combined company”), which today acquired Streamex Exchange Corporation (“Streamex”) as its wholly owned subsidiary, announced the appointment of Mitch Williams, CFA, as Chief Investment Officer, significantly bolstering the combined company’s leadership team and advancing its mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointme ...

Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced successful completion of the previously disclosed share exchange transaction and executive leadership changes, forming a company specializing in the tokenization of real-world assets, with a focus on bringing commodities on-chain. Key Highlights of the Transaction: Streamex Ex ...

Core Viewpoint - BioSig Technologies, Inc. has signed a definitive share exchange agreement with Streamex Exchange Corporation, marking a significant milestone in the business combination aimed at enhancing the tokenization of real-world assets, particularly in the commodities sector [1][2]. Company Overview - BioSig Technologies is a medical technology company focused on innovative solutions, while Streamex specializes in the tokenization of real-world assets, particularly commodities [1][7]. - The combined entity will be led by Henry McPhie, Co-Founder and CEO of Streamex, with Anthony Amato transitioning to a board role [5]. Transaction Highlights - The share exchange will result in Streamex becoming a wholly owned subsidiary of BioSig, with existing Streamex shareholders entitled to receive 75% of the fully diluted BioSig common stock post-transaction [5][12]. - The transaction is expected to unlock new value in the US$142.85 trillion global commodity market by bringing commodities on-chain through secure tokenization solutions [5][13]. Strategic Additions - Notable strategic advisors have joined the combined company, including Frank Giustra, Mathew August, and Mitchell Williams, bringing extensive experience in commodities and capital markets [6]. Market Positioning - Streamex aims to revolutionize commodity finance by bridging traditional finance with the digital economy, enhancing liquidity, accessibility, and efficiency through innovative financial technologies and blockchain [8].

Revenue and Financial Performance - Revenue for the three months ended March 31, 2024 was $14, primarily from the sale of the PURE EP™ Platform and related services[147] - Net loss attributable to common shareholders for the three months ended March 31, 2025 was $2,814, an improvement from a net loss of $3,537 in the same period of 2024[154] - Cash used in operating activities for the three months ended March 31, 2025 was $1.11 million, while cash provided by financing activities totaled $4.7 million[158] - The accumulated deficit as of March 31, 2025 was $258.16 million, with expectations of continued losses and negative cash flows until products reach full commercial profitability[159] - The company sold 4,403,166 At The Market Offering Shares at an average price of $0.91 per share for gross proceeds of $4,019,063 during the three months ended March 31, 2025[170] Expenses - Research and development expenses decreased by $232, or 97.48%, to $6 for the three months ended March 31, 2025, compared to $238 in the same period of 2024[148] - General and administrative expenses increased by $75, or 2.60%, to $2,957 for the three months ended March 31, 2025, compared to $2,882 in the same period of 2024[149] Internal Controls and Compliance - The company identified material weaknesses in internal control over financial reporting, including inadequate identification and reporting of stock-based compensation, ineffective review processes, and inadequate segregation of duties[178] - As of March 31, 2025, the company concluded that its internal control over financial reporting was not effective, which could negatively impact timely and accurate financial reporting[178] - Management's evaluation indicated that disclosure controls and procedures are not effective in providing reasonable assurance for timely reporting as required by SEC rules[175] - The company has not identified any changes in internal control over financial reporting that materially negatively affected its controls during the last completed fiscal quarter[184] - The material weaknesses identified did not result in any misstatements to the consolidated financial statements[180] - The company recognizes the inherent limitations of internal controls, including the possibility of human error and circumvention of controls[182] - Management intends to implement remediation plans in 2025 to enhance internal controls and ensure risks are adequately addressed[184] - The company plans to add sufficient staff and oversight controls in 2025 to address identified deficiencies in internal controls[181] Legal Matters - A settlement agreement was reached on March 24, 2025, resulting in an accrued liability of $493,800 related to a litigation threat claiming losses of approximately $1,440,000[186] - The company believes that the final disposition of legal proceedings will not have a material adverse effect on its financial position or results of operations[185] Intellectual Property - The company has 41 issued/allowed utility patents and 31 pending applications related to the PURE EP™ System, indicating a strong focus on intellectual property development[145] Future Financing - Future financing may include equity or debt securities issuance, with potential dilution for existing shareholders if additional equity is issued[167]

Core Viewpoint - BioSig Technologies, Inc. has entered into a Letter of Intent to merge with Streamex Exchange Corporation in an all-stock transaction, aiming to bring a real-world asset tokenization company public on Nasdaq [1][2] Proposed Transaction Highlights - The merger will create a platform for real-world asset tokenization, focusing on commodities, enhancing investment processes, and increasing capital availability for companies and investors [5][6] - Streamex aims to revolutionize commodity finance by bringing commodity markets on-chain, leveraging advanced financial technologies and blockchain transparency [7] Company Background - Streamex is a real-world asset tokenization company targeting the commodities sector, led by experienced executives from financial, commodities, and blockchain industries [6] - The company believes in the future of finance through tokenization and decentralized markets, aiming to enhance liquidity and accessibility for investors [7] Leadership Changes - Post-merger, Henry McPhie will become the CEO, and Morgan Lekstrom will serve as Chairman of the Board, with Anthony Amato remaining on the Board [12] - Strategic advisors with significant industry experience will be added to the Board, including Frank Giustra, Mathew August, and Mitchell Williams [12] Ownership Structure - After the merger, former stockholders of Streamex will own approximately 75% of the outstanding Common Stock of the combined company, while current BioSig stakeholders will hold the remaining equity [13]

Core Viewpoint - Biosig Technologies, Inc. (BSGM) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system tracks the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts for the current and following years, indicating a changing earnings picture [1][2]. - A strong correlation exists between changes in earnings estimates and near-term stock price movements, with institutional investors using these estimates to determine fair value [4][6]. Company Performance and Outlook - The upgrade for Biosig Technologies suggests an improvement in the company's underlying business, which could lead to increased buying pressure and a rise in stock price [5][10]. - For the fiscal year ending December 2025, Biosig Technologies is expected to earn -$0.20 per share, reflecting a 73.3% change from the previous year, with a 72.6% increase in the Zacks Consensus Estimate over the past three months [8][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - Biosig Technologies' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9][10].

Financial Performance and Funding - BioSig Technologies has generated minimal revenue to date, indicating operations are in an early commercialization stage[17]. - On March 7, 2024, the company issued a promissory note for $500,000 at a 12% interest rate, which was later converted into 348,624 shares of common stock[25][27]. - The company raised approximately $1,040,000 from the sale of 260,720 shares at $3.989 per share on January 12, 2024[28]. - A total of 4,403,166 ATM Shares were sold at an average price of $0.91 per share, generating gross proceeds of $4,019,063 from January 17, 2025, to April 14, 2025[34]. - The company incurred a net loss of $10.3 million and used $4.8 million in cash for operating activities for the year ended December 31, 2024[141]. - As of December 31, 2024, the company's cash and cash equivalents were approximately $0.1 million, which is insufficient to fund operations in the near future[148]. - The company expects to incur substantial additional operating expenses over the next several years as it focuses on marketing, commercialization, and customer development for its PURE EP product[144]. - Future revenue generation from the PURE EP and other products is uncertain and subject to market acceptance and competitive pressures[142]. - The company may need to raise additional funds through public or private equity offerings, debt financings, or corporate collaborations, which may not be on favorable terms[149]. Corporate Structure and Ownership - The company has a majority ownership of 69.08% in ViralClear Pharmaceuticals and 84.5% in BioSig AI Sciences as of April 14, 2025[18][19]. - ViralClear Pharmaceuticals, Inc. is currently dormant, with the company retaining 69.08% ownership as of April 14, 2025[97]. - BioSig AI Sciences, Inc. holds an 84.5% majority interest as of April 14, 2025, but its business operations are currently on hold due to lack of resources[100][101]. Intellectual Property and Patents - The patent portfolio includes 41 issued utility patents and 31 pending applications related to the PURE EP System, with additional patents focused on artificial intelligence[24]. - The company has signed three patent and know-how license agreements with Mayo Foundation, focusing on novel ablation therapy methods[104]. - The company currently holds 41 issued/allowed utility patents and has 31 additional U.S. and foreign utility patent applications pending related to its PURE EP System[206]. - The company has one U.S. patent and one pending application directed to artificial intelligence (AI), along with 30 issued worldwide design patents[206]. - The company plans to file additional patent applications to provide market exclusivity for its products, but cannot predict the outcome of these applications[207]. - The company faces risks related to the enforcement of its intellectual property rights, particularly in foreign jurisdictions where legal systems may not favor patent enforcement[209]. - The company relies on trade secret protection and confidentiality agreements to safeguard proprietary information, but these measures may not provide adequate protection[213]. - The company may face challenges from competitors who could successfully challenge its patent applications or produce similar products[214]. - If the company infringes upon third-party patents, it could face litigation and be prevented from selling its products[216]. Regulatory and Compliance Issues - The company is subject to various U.S. healthcare fraud and abuse laws, which impose civil and criminal penalties for false claims[131]. - The company must comply with Quality System Regulation (QSR) and other FDA requirements for medical device manufacturing[127]. - The company’s PURE EP product is affected by the European Union Medical Device Directive, which requires CE marking for commercial distribution[134]. - The medical device industry is highly regulated, and compliance with FDA regulations is essential for the company's operations and product marketing[162]. - The company may face increased compliance costs due to changing regulations, which could impact its ability to obtain or maintain regulatory approvals for its products[163]. - The company is classified as a "smaller reporting company," which may make it more challenging for investors to analyze its financial prospects due to reduced disclosure requirements[195]. - The company must navigate complex state healthcare laws that may impose broader restrictions than federal laws, increasing compliance risks[184]. - The company has identified a material weakness in its internal control over financial reporting, which could adversely affect its ability to report results accurately and timely[200]. - Remediation of the identified material weakness will require substantial effort throughout 2025 and beyond, with ongoing testing of the effectiveness of new and existing controls[202]. Market and Competitive Landscape - The global electrophysiology laboratory devices market is projected to grow at a CAGR of 15.1% from 2025 to 2030, reaching an estimated USD 12.9 billion in 2024[62]. - Atrial fibrillation (AF) affects nearly 40 million individuals globally, with an estimated 12.1 million cases in the U.S. by 2030, leading to significant healthcare impacts[65]. - The average selling price of competing electrophysiology recording systems is approximately $160,000, indicating a competitive market landscape[93]. - The competitive landscape in the EP market includes major players like GE and Medtronic, which possess greater resources and may develop superior products[167]. - The addressable market size estimate for the EP market may be inaccurate, potentially limiting future growth prospects[165]. Product Development and Clinical Trials - The PURE EP™ Platform aims to improve the quality of cardiac signal recordings, addressing limitations in current electrophysiology recording systems[75]. - Clinical evaluations showed a 75% overall improvement in intracardiac signal quality and an 83% improved confidence in interpreting complex signals compared to conventional sources[88]. - The PURE EP™ System has been tested in 24 pre-clinical studies, with 21 conducted at Mayo Clinic, validating its clinical effectiveness[82]. - The system's design allows for the acquisition of high-fidelity signals with minimal noise, enhancing the diagnostic value of cardiac signals[76]. - The PURE EP™ System has shown potential to reduce the need for multiple ablation procedures, improving patient outcomes[79]. - The company has completed one clinical trial, but further studies may not support the usefulness of its technology[139]. - The company relies on collaboration with Mayo Clinic for research and development of PURE EP's advanced features[140]. Operational Challenges and Workforce - The Company faced workforce reductions, laying off 42 employees in early 2024 due to funding issues, leaving only the CEO[51][53]. - The Company currently has 5 employees and 3 key consultants, with plans to hire 4-6 additional staff depending on funding[58]. - The company is highly dependent on key personnel, and their loss could adversely affect product development and operational efficiency[168]. Risks and Uncertainties - The company faces substantial doubt about its ability to continue as a going concern due to its development stage[139]. - The company expects to incur operating losses as it reverts to a development stage[139]. - The company faces risks related to the development and commercialization of its technology, including potential delays and the need for additional capital[151]. - Cybersecurity risks are a growing concern, with potential impacts on financial condition and operational integrity[179]. - The company may face product liability claims, which could result in significant financial liabilities and reputational damage[178]. - Violations of healthcare laws could result in substantial penalties, including exclusion from federal healthcare programs like Medicare and Medicaid, and reputational harm[186]. - Changes in U.S. healthcare legislation, such as the Healthcare Reform Law, could negatively impact the company's revenue and market for its products[191]. - Global economic uncertainty and geopolitical tensions could hinder the company's ability to raise capital and disrupt its supply chain for research and development[197].